A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 6, 2010, Pages 862-866

  Spigel, David R ^a,b   Hainsworth, John D ^a,b   Gandhi, Jitendra G ^c   Gian, Victor G ^a   Peyton, James D ^a   West Osterfield, Kimberly ^a   Clark, Bobby L ^a   Vazquez, Elizabeth R ^a   Jones, Suzanne F ^a   Burris, Howard A ^a,b   Greco, F Anthony ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Associates in Oncology and Hematology   (United States)

Author keywords

Carboplatin; Extensive stage; First line; Small cell lung cancer; Topotecan

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DEHYDRATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TOXICITY; TREATMENT RESPONSE; CARCINOMA, SMALL CELL; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TOPOTECAN;

EID: 77953160643     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d86a4f     Document Type: Article

References (26)

1. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043.
2. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008;26:4261-4267.
3. Natale RB, Lara PN, Chansky K, et al. S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol 2008;26 (suppl 15) : 7512.
4. Schmittel A, Fischer von Weikersthal L, Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006;17:663-667.
5. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
6. Christodoulou C, Kalofonos HP, Briasoulis E, et al. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG). Cancer Chemother Pharmacol 2006;57:207-212.
7. Seifart U, Fink T, Schade-Brittinger C, et al. Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Ann Oncol 2007;18:104-109.
8. Sorensen M, Lassen U, Jensen PB, et al. Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease. J Thorac Oncol 2008;3:902-906.
9. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006;24:2044-2051.
10. Eckardt JR. Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 2004;9 (suppl 6) : 25-32.
11. Rowinsky EK. Weekly topotecan: an alternative to topotecan's standard daily × 5 schedule? Oncologist 2002;7:324-330.
12. Bhoola SM, Coleman RL, Herzog T, et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 2004;95:564-569.
13. Homesley HD, Hall DJ, Martin DA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001;83:394-399.
14. Largillier R, Valenza B, Ferrero JM, et al. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology 2007;73:177-184.
15. Morris RT. Weekly topotecan in the management of ovarian cancer. Gynecol Oncol 2003;90 (3 Pt 2) : S34-S38.
16. Traina TA, Sabbatini P, Aghajanian C, et al. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecol Oncol 2004;95:235-241.
17. Murphy PB, Hainsworth JD, Spigel DR, et al. Topotecan-single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC) : a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2006;24 (suppl 18) : 17000.
18. Shipley DL, Hainsworth JD, Spigel DR, et al. Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC) : a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2006;24 (suppl 18) : 7083.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
20. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
22. Rose PG, Smrekar M, Haba P, et al. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecol Oncol 2005;99:714-719. (Pubitemid 41686557)
23. Schwartz PE, Rose PG, Monk BJ, et al. An open-label, single arm, phase II study of IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21 days as second-line therapy in subjects with platinum-sensitive relapsed ovarian cancer: first stage results. J Clin Oncol 2008;26 (suppl 15) : 16518.
24. Smrekar M, Buller RE, Haba P, et al. A phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma. J Clin Oncol 2004;22 (suppl 14) : 5147.
25. Shah C, Ready N, Perry M, et al. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 2007;57:84-88.
26. Shipley D, Spigel DR, Hainsworth JD, et al. Phase II trial of high-dose weekly topotecan in patients with relapsed small-cell lung cancer (SCLC). J Clin Oncol 2008;26 (suppl 15) : 19073.